---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031300"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:34:24.967302+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed completes last patient visit in Phase 2b DLB trial; topline data expected Dec 2024

## Summary
- Last patient last visit completed in Phase 2b RewinD-LB trial evaluating neflamapimod in early-stage DLB.
- 96% of patients completed the 16-week double-blind placebo-controlled portion; 98% continued into open-label extension.
- DSMB concluded study may proceed without modification after pre-specified safety data review.
- Company on track to report topline efficacy and safety data in December 2024.
- Late-breaking oral presentations on plasma biomarker data planned at upcoming CTAD conference.

## SEC filing metadata
- accession: 0001437749-24-031300
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924031300/0001437749-24-031300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924031300/crvo20241015_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031300
- JSON: https://secwatch.observer/filing/0001437749-24-031300.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.